摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7S,8,17R-triHDHA | 623582-58-1

中文名称
——
中文别名
——
英文名称
7S,8,17R-triHDHA
英文别名
(4Z,7S,9E,11E,13Z,15E,17R,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
7S,8,17R-triHDHA化学式
CAS
623582-58-1
化学式
C22H32O5
mdl
——
分子量
376.493
InChiKey
OIWTWACQMDFHJG-WEXUSCBHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    27
  • 可旋转键数:
    14
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    98
  • 氢给体数:
    4
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    7(S)-epoxy-17R-HDHA 生成 7S,8,17R-triHDHA 、 7S,16,17R-triHDHA
    参考文献:
    名称:
    [EN] USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
    [FR] UTILISATION DE DOCOSATRIENES, RESOLVINES ET LEURS ANALOGUES STABLES POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES ET DE L'ASTHME
    摘要:
    公开号:
    WO2005089744A3
点击查看最新优质反应信息

文献信息

  • NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID
    申请人:The University of Tokyo
    公开号:EP2607358A1
    公开(公告)日:2013-06-26
    The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, d ocosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations.
    目的是提供一种能克服传统类固醇药物和非甾体抗炎药缺点的化合物。研究发现,由式[化学式 1]、[化学式 5]等独立表示的二十碳五烯酸、二十二碳六烯酸和二十二碳五烯酸的特定环氧单羟基形式对中性粒细胞具有抑制活性。这种化合物可抑制中性粒细胞侵入组织和中性粒细胞的活化,这在急性炎症中是可以观察到的。
  • NOVEL ANTI-INFLAMMATORY COMPOUNDS
    申请人:Arita Makoto
    公开号:US20120059061A1
    公开(公告)日:2012-03-08
    An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.
  • US8853437B2
    申请人:——
    公开号:US8853437B2
    公开(公告)日:2014-10-07
  • US9238634B2
    申请人:——
    公开号:US9238634B2
    公开(公告)日:2016-01-19
查看更多